Assessment of the impact of treatment on quality of life of patients with haemophilia A at different ages: insights from two clinical trials on turoctocog alfa
Haemophilia and its treatment interfere with patients' life, so health-related quality of life (HRQoL) should be assessed when evaluating treatments. This study investigated the HRQoL of patients with haemophilia A treated prophylactically with a new recombinant factor VIII. Two phase 3 trials...
Main Authors: | Santagostino, E, Lentz, S R, Busk, A K, Regnault, A, Iorio, A |
---|---|
Format: | Online |
Language: | English |
Published: |
BlackWell Publishing Ltd
2014
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4282346/ |
Similar Items
-
Safety and efficacy of turoctocog alfa (NovoEight®) during surgery in patients with haemophilia A: results from the multinational guardian™ clinical trials
by: Santagostino, E, et al.
Published: (2015) -
Turoctocog alfa: an evidence-based review of its potential in the treatment of hemophilia A
by: Takedani, Hideyuki, et al.
Published: (2015) -
Turoctocog alfa (NovoEight®) – from design to clinical proof of concept
by: Ezban, Mirella, et al.
Published: (2014) -
Molecular design and downstream processing of turoctocog alfa (NovoEight), a B-domain truncated factor VIII molecule
by: Ahmadian, Haleh, et al.
Published: (2016) -
The Effect of Yoga on the Quality of Life in the Children and Adolescents with Haemophilia
by: Beheshtipoor, Noushin, et al.
Published: (2015)